Company Overview

Update
Headquarters:
Rotterdam Alexanderpolder
IPO:
Went Public on Jul 10, 2014
Stock:
ARGX
Categories:
Biotechnology
Description:
arGEN-X has invented and developed a platform for antibody lead choice in the discovery of human antibody therapeutics.

Detailed Description

Update

To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics.

Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.

Investors (11)

Update

Offices/Locations (1)

Update
  • HQ

    Dr Molewaterplein 50

    Rotterdam Alexanderpolder, 3015

    NLD